)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Jagsonpal Pharmaceuticals
Jagsonpal Pharmaceuticals (JAGSNPHARM) investor relations material
Jagsonpal Pharmaceuticals Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary29 Oct, 2026
Executive summary
Q2 core business grew 9.3% like for like; consolidated revenue was ₹963.71 million, up 29% with Aequitas included. Growth is expected to accelerate from Q3 as the Wellness portfolio contributes.
H1 organic growth was 9.3%; investments in launches, people and capabilities supported the long-term goal of ₹5,000 million revenue by FY28, targeted through organic growth without further acquisitions.
Acquisitions broadened hospital, institutional and therapy reach; management expects Q3 revenue above ₹1,000 million and EBITDA-accretive growth.
Financial highlights
Standalone Q2 revenue was ₹813.75 million, up 9.3% YoY; EBITDA before ESOP cost was ₹185 million and PAT was ₹125.90 million.
Standalone H1 revenue was ₹1,636.07 million, up 9.0%; EBITDA before ESOP cost was ₹375 million and PAT was ₹257.79 million.
Consolidated Q2 revenue was ₹963.71 million, EBITDA before ESOP cost ₹186 million and PAT ₹122.87 million; H1 revenue was ₹1,786.03 million, EBITDA ₹377 million and PAT ₹254.76 million.
Standalone gross margin expanded 70 bps in Q2 and 75 bps in H1; gross profit contribution increased 10.5% and 10.3%, respectively.
Consolidated H1 net operating cash generation was ₹254.65 million; cash and bank balances were ₹1,360 million consolidated and ₹1,347 million standalone at 30 September 2026.
Outlook and guidance
The FY28 Mission 2028 revenue target is ₹5,000 million, versus FY26 revenue of ₹2,872 million; the target is based on organic growth and the current portfolio, excluding further acquisitions.
Q3FY27 revenue is expected to exceed ₹1,000 million, with growth above 1.5x expected pharma-industry growth and EBITDA-accretive growth.
Collective EBITDA margins are expected to exceed 22% longer term; Q3 consolidated margin is expected near 22% or higher, while Q4 seasonality may weigh on margins.
Standalone gross margin is expected to improve 50–75 bps YoY from near 65%, driven by mix and price increases; Aequitas reset benefits are expected from Q4, with an approximately ₹10 crore EBITDA target by 2028.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Jagsonpal Pharmaceuticals
- Acquisition of a wellness portfolio accelerates growth, expands reach, and enhances profitability.JAGSNPHARM
Investor presentation - Q1 FY27 delivered strong growth, margin expansion, and strategic acquisition-led scale.JAGSNPHARMQ1 26/27
- FY26 saw 7% revenue growth, 19% profit rise, and major shareholder returns via dividend and buyback.JAGSNPHARMQ4 25/26
- Nine-month revenue up 6% YoY, PAT up 12.5%, with strong cash and growth focus.JAGSNPHARMQ3 25/26
- H1 FY26 revenue up 10% and PAT up 39%, with strong cash and stable Q2 performance.JAGSNPHARMQ2 25/26
- Q1FY25 saw strong revenue growth, margin expansion, and a major acquisition integration.JAGSNPHARMQ1 24/25
- Q2 revenue up 29.2% and net profit up 53%, with stock split and strategic acquisition completed.JAGSNPHARMQ2 24/25
- Quarterly profit surged on a one-time gain and strong revenue growth, aided by acquisitions.JAGSNPHARMQ3 24/25
- FY25 saw record revenue, margin gains, and profit surge, fueled by acquisitions and asset sales.JAGSNPHARMQ4 24/25
Next Jagsonpal Pharmaceuticals earnings date
Q3 26/2721 Jan, 2027
Jagsonpal Pharmaceuticals
Next Jagsonpal Pharmaceuticals earnings date
Q3 26/2721 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Jagsonpal Pharmaceuticals Limited is a pharmaceutical company engaged in the development, manufacturing, and marketing of branded generic formulations. The company offers a range of dosage forms including tablets, capsules, syrups, and injectables across therapeutic segments such as gynecology, orthopedics, dermatology, and general medicine. It serves domestic and international markets through an established distribution network and field force. The company is headquartered in New Delhi, India, and its shares are listed on the BSE.